Early detection of tumor response to chemotherapy by 3′-deoxy- 3′-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4202-4210

  Leyton, Julius ^a   Latigo, John R ^a   Perumal, Meg ^a   Dhaliwal, Harmandeep ^a   He, Qimin ^b   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; ADENOSINE TRIPHOSPHATE; CISPLATIN; CYCLINE; FLUORINE 18; HEXOKINASE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG TUMOR LEVEL; EQUIPMENT; FIBROSARCOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; METAPHASE; MOUSE; NONHUMAN; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION CARCINOGENESIS; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CISPLATIN; DIDEOXYNUCLEOSIDES; FIBROSARCOMA; FLUORINE RADIOISOTOPES; HEXOKINASE; MALE; MICE; MICE, INBRED C3H; NEOPLASMS, RADIATION-INDUCED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMIDINE KINASE;

EID: 20144366731     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4008     Document Type: Article

References (50)

1. 1H nuclear magnetic resonance spectroscopy: Effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res 1998;58:1063-7.
2. Fenton JJ, Weiss NS. Screening computed tomography. Cancer 2004;100:986-90.
3. Jayasekera N. Does CT screening for lung cancer assist smokers to stop? Thorax 2004;59:230.
4. Bock NA, Zadeh G, Davidson LM, et al. High-resolution longitudinal screening with magnetic resonance imaging in a murine brain cancer model. Neoplasia 2003;5:546-54.
5. Zinreich SJ. Imaging in laryngeal cancer: computer tomography, magnetic resonance imaging, positron emission tomography. Otolaryngol Clin North Am 2002;35:971-91.
6. Whiteford MH, Yee LF, Ogunbiyi OA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;42:759-67.
7. Kaliff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenies AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2000;43:429-99.
8. Arulampalam TH, Ledermann J, Costa DC. Asymptomatic patient with an increased concentration of CEA. Lancet Oncol 2001;2:172.
9. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
10. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studies by microautoradiography. J Nucl Med 1992;33:1972-80.
11. Bakhee SM, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J. FDG uptake in breast infection and inflammation. Clin Nucl Med 2000;25:100-3.
12. 18F]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
13. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase. I. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
14. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8.
15. Duvillard C, Ponelle T, Chapusot C, Piard F, Romanet P, Chauffert B. EDTA enhances the antitumor efficacy of intratumoral cisplatin in s.c. grafted rat colon tumours. Anticancer Drugs 2004;15:295-9.
16. Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer 2003;106:699-705.
17. Niibe Y, Karasawa K, Hayakawa K. Ten-year disease-free survival of a small cell lung cancer patient with brain metastasis treated with chemoradiotherapy. Anticancer Res 2004;24:2097-100.
18. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treatment Rev 1998;24:331-44.
19. 18F]FLT) and the fate of the precursor 2,3′-anhydro-5′-O- (4-4′-dimethoxytrityl)-thymidine. J Labeled Compounds Radiopharm 2001;27:235-8.
20. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
21. 18F]Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
22. Schimke RT, Grossbard L. Multiple hexokinase of rat tissue. Purification and comparison of soluble forms. J Biol Chem 1966;214:3546.
23. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
24. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cell? In virto comparison with DNA flow cytometry and tritated thymidine uptake. J Nucl Med 1993;34:414-9.
25. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31:S80-7.
26. Eastman A, Kohn EA, Brown MK, et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002;1:1067-78.
27. Cherry SM, Hunt PA, Hassold TJ. Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation. Mutat Res 2004;564:115-28.
28. Qin LF, Ng IO. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Cancer Lett 2001;175:27-38.
29. Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol Oncol 2002;84:404-12.
30. Demarcq C, Bastian G, Remvikos Y. BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells. Cytometry 1992;13:416-22.
31. Celis JE, Celis A. Cell cycle-dependent variations of the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A 1985;82:3262-6.
32. Mathews MB, Bernstein RM, Franza BRJ. Garrels J. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984;309:374-6.
33. Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose treatment in murine tumour model. Nucl Med Biol 1996;23:533-41.
34. Nottebrock H, Then R. Thymidine concentrations in serum and urine in different animal species and man. Biochem Pharmacol 1977;26:2175-9.
35. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
36. Buck AK, Schirrmeister H, Hetze IM, et al. 3-Deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
37. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44.
38. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
39. Sutterluety H, Bartl S, Dötzlhofer A, Khier H, Wintersberger E, Seiser C. Growth-regulated antisense transcription of the mouse thymidine kinase gene. Nucleic Acids Res 1998;26:4989-95.
40. Tommasi S, Pfeifer GP. Constitutive protection of E2F recognition sequences in the human thymidine kinase promotor during cell cycle progression. J Biol Chem 1997;272:30483-90.
41. Sorensen P, Wintersberger E. Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promotor. J Biol Chem 1999;274:30943-9.
42. Chang AF, Huang DY, Hsue NC. Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 1994;269:21249-54.
43. Chang ZF, Huang DY, Chi LM. Serine 13 is the site of mitotic phosphorylation of human thymidine kinase. J Biol Chem 1998;273:12095-100.
44. Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 2004;24:514-26.
45. Li CH, Lu CY, Ke PO, Chang ZF. Perturbation of ATP-induced tetramerization of human cytosolic thymidine kinase by substitution of serine-13 with aspartic acid at the mitotic phosphorylation site. Biochem Biophys Res Commun 2004;313:587-93.
46. Wang D, Lippard SJ. Cisplatin-induced post-translational modification of histones H3 and H4. J Biol Chem 2004;279:20622-5.
47. Andrews BJ, Turchi J. Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. J Mol Cancer Ther 2004;3:385-91.
48. O'Connor PM, Fan S. DNA damage checkpoints: implications for cancer therapy. Prog Cell Cycle Res 1996;2:165-73.
49. Barthel H, Price P, Aboagye EO. Small-animal imaging of tumour proliferation with PET. Lancet Oncol 2004;5:100.
50. Munch-Petersen B, Cloos L, Tyrsted G, Erikson S. Diverging substrate specificity of pure human thymidine kinase 1 and 2 against antiviral dideoxynucleotides. J Biol Chem 1991;266:9032-8.